FORM D

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D



NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

OMB	APPROVAL	

OMB Number: 3235-0076 Expires: April 30, 2008

Estimated average burden hours per response...... 16.00

SEC USE ONLY					
Prefix	Serial				
DATE R	ECEIVED				
l I	1				

Name of Offering Leheck if this is an amendment and name has changed, and indicate change.)			
Cabrellis Pharmaceuticals Corporation - Series A Preferred Stock Filing Under (Check box(es) that apply): Rule 504 Rule 505 Rule 506 Section 4(6) Type of Filing: New Filing Amendment			
A. BASIC IDENTIFICATION DATA			
1. Enter the information requested about the issuer		06020140	
Name of Issuer (check if this is an amendment and name has changed, and indicate change.) Cabrellis Pharmaceuticals Corporation			
Address of Executive Offices (Number and Street, City, State, Zip Code) 9393 Towne Centre Drive, Suite 210, San Diego, CA 92121-3070	Telephone Number (858) 404-71	(Including Area Code) 11	
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices) same	Telephone Number same	(Including Area Code)	
Brief Description of Business Pharmaceutical products		PROCESSED	
Type of Business Organization ☐ corporation ☐ limited partnership, already formed ☐ business trust ☐ limited partnership, to be formed	other (ple	ase specify): AUG 2 1 2006	
Actual or Estimated Date of Incorporation or Organization: Month Year	☑ Actual ☐ Estimate:	THOMSON FINANCIAL	
CN for Canada; FN for other foreign jurisdiction)		DE	
GENERAL INSTRUCTIONS			
Federal: Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation I	D or Section 4(6), 17 (CFR 230.501 et seq. or 15 U.S.C. 77d(6).	
When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if receive mailed by United States registered or certified mail to that address.			
Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20	0549.		
Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be photocopies of the manually signed copy or bear typed or printed signatures.	e manually signed.	Any copies not manually signed must be	
Information Required: A new filing must contain all information requested. Amendments need only rethe information requested in Part C, and any material changes from the information previously supplies with the SEC.			

Filing Fee: There is no federal filing fee.

State

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

SEC 1972 (5-05)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a current valid OMB control number.

1 of 9

	A DA	SIC IDENTIFICATION	IDATA		
 Enter the information requested for the Each promoter of the issuer, if the Each beneficial owner having the Each executive officer and directo Each general and managing partner 	following: issuer has been organized power to vote or dispose, r of corporate issuers and	or direct the vote or dispo	s; sition of, 10% o		ass of equity securities of the issuer; hip issuers; and
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	□ Director	General :	and/or g Partner
Full Name (Last name first, if individual) Collinson, Ph.D., Stuart J.M.				ivialiagiii	E I mino
Business or Residence Address (Number a c/o Forward Ventures, 9393 Towne Centr		•			
Check Box(es) that Apply: Promoter	☐ Beneficial Owner	Executive Officer	□ Director	General Managin	and/or g Partner
Full Name (Last name first, if individual) Schreiber, M.D., Alain B.					
Business or Residence Address (Number a c/o ProQuest Investments, 90 Nassau Stre					
Check Box(es) that Apply: Promoter	☐ Beneficial Owner	Executive Officer	□ Director	General Managir	and/or g Partner
Full Name (Last name first, if individual) Weber, Eckard					
Business or Residence Address (Number a c/o Domain Associates, One Palmer Squa		Code)			
Check Box(es) that Apply: Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	General Managir	and/or g Partner
Full Name (Last name first, if individual) Torres, S. Edward					
Business or Residence Address (Number a c/o Eli Lilly & Company, Lilly Corporate	and Street, City, State, Zip Center, Indianapolis, I		1-2		
Check Box(es) that Apply: Promoter	☑ Beneficial Owner		☑ Director	☐ General Managir	and/or g Partner
Full Name (Last name first, if individual) Estok, Thomas M.					
Business or Residence Address (Number a c/o Cabrellis Pharmaceuticals Corporation		•	go, CA 92121-3	070	
Check Box(es) that Apply: Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	General Managir	and/or
Full Name (Last name first, if individual) Fritz, Lawrence C.					
Business or Residence Address (Number a 14530 Calle Carla, Rancho Santa Fe, CA	•	o Code)			
Check Box(es) that Apply:	☐ Beneficial Owner	Executive Officer	☐ Director	General Managir	and/or and/or and/or
Full Name (Last name first, if individual) Crawford, John E.					
Business or Residence Address (Number a c/o Cabrellis Pharmaceuticals Corporation	-		go, CA 92121-3	070	
	(Use blank sheet, or copy	and use additional copies	s of this sheet, as	necessary.)	

		SIC IDENTIFICATION	DATA		
 Enter the information requested for the Each promoter of the issuer, if the Each beneficial owner having the Each executive officer and directo Each general and managing partner 	issuer has been organized power to vote or dispose, or of corporate issuers and	or direct the vote or dispo	sition of, 10% o		uss of equity securities of the issuer; hip issuers; and
Check Box(es) that Apply:	☐ Beneficial Owner	Executive Officer	☐ Director	General a	and/or g Partner
Full Name (Last name first, if individual) LeMasters, Christopher C.					
business or Residence Address (Number a o Cabrellis Pharmaceuticals Corporation		*	go, CA 92121-30	070	
Check Box(es) that Apply:	Beneficial Owner	Executive Officer	☐ Director	General a	and/or g Partner
Full Name (Last name first, if individual) ProQuest Investments III, L.P.					
Business or Residence Address (Number and Number and Nassau Street, 5 th Floor, Princeton, NJ		Code)			
Check Box(es) that Apply: Promoter	☑ Beneficial Owner	☐ Executive Officer	Director	General :	and/or g Partner
Full Name (Last name first, if individual) S.R. One, Limited					
Business or Residence Address (Number a Four Tower Bridge, 200 Barr Harbor Dr	-				
Check Box(es) that Apply: Promoter	Beneficial Owner	☐ Executive Officer	☐ Director	General Managin	and/or g Partner
Full Name (Last name first, if individual) Forward Ventures V, L.P.					
Business or Residence Address (Number a) 393 Towne Centre Drive, Suite 200, San		Code)			
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	☐ Director	General Managir	and/or g Partner
Full Name (Last name first, if individual) Domain Partners V, L.P.					
Business or Residence Address (Number c/o Domain Associates, One Palmer Squa		Code)			
Check Box(es) that Apply: Promoter	Beneficial Owner	☐ Executive Officer	Director	General Managir	and/or ng Partner
Full Name (Last name first, if individual) Lilly Ventures/Eli Lilly & Company					
Business or Residence Address (Number Lilly Corporate Center, Indianapolis, IN	-	Code)			
Check Box(es) that Apply:	☐ Beneficial Owner	Executive Officer	☐ Director	General Managir	and/or ig Partner
Full Name (Last name first, if individual)					
Business or Residence Address (Number	and Street, City, State, Zip	Code)			
	(Use blank sheet, or copy	and use additional copies	s of this sheet, as	necessary.)	

.

B. INFORMATION ABOUT OFFERING								
Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering? Answer also in Appendix, Column 2, if filing under ULOE. What is the minimum investment that will be accepted from any individual?	\$3.30							
Does the offering permit joint ownership of a single unit?	Yes No ⊠							
Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.								
Full Name (Last name first, if individual) Not Applicable								
Business or Residence Address (Number and Street, City, State, Zip Code)								
Name of Associated Broker or Dealer								
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	☐ All States							
AL	☐ GA ☐ HI ☐ ID ☐ MN ☐ MS ☐ MO ☐ OK ☐ OR ☐ PA ☐ WI ☐ PR							
Full Name (Last name first, if individual)								
Business or Residence Address (Number and Street, City, State, Zip Code)								
Name of Associated Broker or Dealer								
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	☐ All States							
AL	GA							
Full Name (Last name first, if individual)								
Business or Residence Address (Number and Street, City, State, Zip Code)								
Name of Associated Broker or Dealer								
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	□ 411 Oc. :							
(Check "All States") or check individual States) □ AL □ AK □ AZ □ AR □ CO □ CT □ DC □ FL □ IL □ IN □ IA □ KS □ KY □ LA □ ME □ MD □ MA □ MI □ MT □ NE □ NV □ NH □ NJ □ NM □ NY □ NC □ ND □ OH □ RI □ SC □ SD □ TN □ TX □ UT □ VT □ VA □ WA □ WV	☐ GA ☐ HI ☐ ID ☐ MN ☐ MS ☐ MO ☐ OK ☐ OR ☐ PA ☐ WI ☐ WY ☐ PR							
(Use blank sheet, or copy and use additional copies of this sheet, as necessar	y.)							

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\square\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate	Amount Already
	Type of Security	Offering Price	Sold
	Debt	\$0.00	\$0.00
	Equity	\$27,500,005.50	\$27,500,005.50
	☐ Common ☒ Preferred Convertible		
	Convertible Securities (including warrants)	\$0.00	\$0.00
	Partnership Interests	\$0.00	\$0.00
	Other (Specify)	\$0.00	\$0.00
	Total	\$27,500,005.50	\$27,500,005.50
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
		Number Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	16	\$27,500,005.50
	Non-accredited Investors	<u> </u>	\$0.00
	Total (for filings under Rule 504 only)		
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		
	Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		
	Regulation A		
	Rule 504		
	Total		
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$0.00
	Printing and Engraving Costs		\$0.00
	Legal Fees		\$45,000.00
	Accounting Fees		\$0.00
	Engineering Fees		\$0.00
	Sales Commissions (specify finders' fees separately)		\$0.00
	Other Expenses (identify)		\$0.00
	Total	_	\$45,000.00
		1	

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

 b. Enter the difference between the aggregate offering total expenses furnished in response to Part C - Que proceeds to the issuer." 5. Indicate below the amount of the adjusted gross proceeds to purposes shown. If the amount for any purpose is not know the estimate. The total of the payments listed must equal 	stion 4.a. This difference is the "adjusted gross to the issuer used or proposed to be used for each of the wn, furnish an estimate and check the box to the left of				<u>\$27,455,005.50</u>
response to Part C - Question 4.b above.			Payments to Officers, Directors, & Affiliates		Payments to Others
Salaries and fees		. 🗆 _	\$0.	<u>oo</u> 🗆	\$0.00
Purchase of real estate			\$0.	<u>00</u> 🗆	\$0.00
Purchase, rental or leasing and installation of mach	inery and equipment	. 🗆 _	\$0.	00 🗆	\$0.00
Construction or leasing of plant buildings and facil	ities	. 🗆 _	\$0.	00 🗆	\$0.00
Acquisition of other business (including the value offering that may be used in exchange for the asset	s or securities of another	П	\$0.	00 🗆	\$0.00
• •					\$0.00
Other (specify): Shares of stock issued upon conve	nucion of coutoin outstanding convoutible	. ⊔ _	\$0.	<u>00</u> ⊠	\$21,350,030.72
notes, including accrued interest. There were no					
			\$0.	<u>00</u> 🛛	\$6,104,974.78
Column Totals		. 🗆 _	\$0.	<u>00</u> 🗵	\$27,455,005.50
	D. FEDERAL SIGNATURE		⊠	\$27,455	
The issuer has duly caused this notice to be signed by the usen undertaking by the issuer to furnish to the U.S. Securities non-accredited investor pursuant to paragraph (b)(2) of Rule	es and Exchange Commission, upon written request				
lssuer (Print or Type) Cabrellis Pharmaceuticals Corporation	Signature In MEN		Date	1/10/0	6
Name of Signer (Print or Type)	Title of Signer (Print or Type)				
Thomas M. Estok	President and Chief Executive Officer				
	ATTENTION				
Intentional misstatements or omissions of fa		s. (See	18 U.S.C. 1	001.)	

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS